Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Myriad's Ovarian Cancer Test Proves Its Mettle as Tesaro Companion Dx

Executive Summary

Myriad’s myChoice HRD test has demonstrated its ability to identify more than twice as many ovarian cancer patients who may benefit from treatment with Tesaro’s drug investigational drug niraparib, compared with patient stratification by germline-BRCA testing alone.

You may also be interested in...

Keeping Track: Novartis' Ribociclib, Tesaro's Niraparib Submitted; Catalyst Clears Path For Firdapse Resubmission

In retrospect, the European Society for Medical Oncology meeting was a showcase for pivotal trial data included in a burst of targeted therapy new drug applications, and more drug development news and highlights from our FDA Performance Tracker.

Lynparza May Still Rival Tesaro's Niraparib In Ovarian Cancer Therapy

AstraZeneca hopes "robust" data from its Phase III SOLO-2 trial will pave the way for its PARP-inhibitor Lynparza (olaparib) to be used in the US market as a maintenance therapy in BRCA-mutated second-line ovarian cancer. But some analysts think FDA may want more proof before giving the okay.

Tesaro Takes Lead: Ovarian Cancer PhIII Pushes Niraparib Ahead Of Clovis' PARP Inhibitor

Positive Phase III data for Tesaro's PARP inhibitor, niraparib, have edged the drug ahead of its pipeline competitors and set the company up to give AstraZeneca's marketed therapy, Lynparza, a run for its money – but will modest PFS results be enough to convince regulators to grant a broader ovarian cancer approval for niraparib?

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts